I highly recommend you look into the work of Joao Pedro de Magalhaes, who is doing diverse and interesting work in aging bioinformatics and aging science in general. Some excellent recent papers: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4203147/ http://www.nature.com/nrc/journal/v13/n5/abs/nrc3497.html and http://www.tandfonline.com/doi/abs/10.4161/15384101.2014.950151
Imagine you had the following at your disposal:
Imagine that your goal were to slow or prevent biological aging...
Thanks for your input.
Update
I thank everyone for their input and apologize for how long it has taken me to post an update.
I met with Aubrey de Grey and he recommended using the anonymized patient data to look for novel uses for already-prescribed drugs. He also suggested I do a comparison of existing longitudinal studies (e.g. Framingham) and the equivalent data elements from our data warehouse. I asked him that if he runs into any researchers with promising theories or methods but for a massive human dataset to test them on, to send them my way.
My original question was a bit to broad in retrospect: I should have focused more on how to best leverage the capabilities my project already has in place rather than a more general "what should I do with myself" kind of appeal. On the other hand, at the time I might have been less confident about the project's success than I am now. Though the conversation immediately went off into prospective experiments rather than analyzing existing data, there were some great ideas there that may yet become practical to implement.
At any rate, a lot of this has been overcome by events. In the last six months I realized that before we even get to the bifurcation point between longevity and other research areas, there are a crapload of technical, logistical, and organizational problems to solve. I no longer have any doubt that these real problems are worth solving, my team is well positioned to solve many of them, and the solutions will significantly accelerate research in many areas including longevity. We have institutional support, we have a credible revenue stream, and no shortage of promising directions to pursue. The limiting factor now is people-hours. So, we are recruiting.
Thanks again to everyone for their feedback.